CHMP, CMDh Recommend a Change in Names of Liposomal Medicines to Avoid Errors

News
Article

CHMP and CMDh have recommended that all marketing authorization holders (MAHs) of medicines containing liposomal drug delivery systems change the medicine name to avoid medication errors.

In a July 31, 2019 news release from the European Medicines Agency (EMA), it was announced that all marketing authorization holders (MAHs) of medicines containing liposomal drug delivery systems change the medicine name to avoid medication errors.

The recommendation has been made jointly by the Committee of Medicinal Products for Human Use (CHMP) and the Coordination Group for Mutual Recognition and Decentralized Procedures-Human (CMDh) during the July meetings. The recommendation is aimed at ensuring there is a clearer distinction between liposomal and non-liposomal formulations of the same active substance, so that errors can be avoided.

There are concerns about serious health issues, which in some instances may lead to death, that have arisen as a result of a number of reports of medication errors. As liposomal and non-liposomal medications have different biodistribution and release properties, medication errors pose a significant risk to patient health. 

Particular concern has been raised over electronic prescribing and dispensing, as potential medication mix-ups may happen in the absence of clear distinction between liposomal and non-liposomal medicines. Name changes to the medicines will also help healthcare professionals and patients to more easily distinguish the medicines.

All MAHs of medicines with liposomal and pegylated liposomal delivery systems have been requested to submit an A.2.a variation before the end of September 2019 to update product names in line with the recommendation.

Source: EMA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content